A Study Of The Effect Of CJ-023,423 On The Incidence Of Stomach Ulcers
Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
CJ-023,423 is a new medication being developed as an anti-inflammatory agent for the
treatment of the signs and symptoms of osteoarthritis (OA). The purpose of this study is to
evaluate whether patients treated with CJ-023,423 for 7 days (14 doses) have fewer
gastrointestinal ulcers compared to patients treated with naproxen and placebo.